NEW YORK (GenomeWeb News) – Veracyte today announced that private payor UnitedHealthcare has issued a positive medical coverage policy for the firm's molecular diagnostic test for thyroid cancer.

The decision by UHC, which covers about 27 million commercial members, pertains to Veracyte's Afirma Gene Expression Classifier for assessing thyroid nodule fine needle aspirate biopsies that are neither clearly benign nor malignant based on cytology review. The policy takes effect April 1.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.